Telomir Pharmaceuticals, Inc. (TELO) - 8-K Summary
Business Context and Reporting Period
This Form 8-K, dated February 17, 2026, reports on preclinical developments for Telomir Pharmaceuticals, Inc., an emerging growth company incorporated in Florida. The filing details new in vitro data for the investigational compound Telomir-1 (Telomir-Zn) in human triple-negative breast cancer (TNBC) models.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on scientific and clinical development milestones rather than financial performance.
Material Changes and Scientific Developments
- Tumor Cell Mortality: Telomir-Zn demonstrated broad efficacy across multiple TNBC cell lines at 72 hours. Near-complete mortality was observed in MDA-MB-468 (Basal-A/EGFR-high), while significant partial reductions were seen in HCC70 (Basal-like) and MDA-MB-231 (Claudin-low/mesenchymal).
- Mechanism of Action: Iron-rescue experiments confirmed that the addition of supplemental iron attenuated tumor cell mortality, supporting an iron-dependent mechanism consistent with intracellular metal-modulating activity.
- Ongoing Evaluations: Two additional cell lines (BT-549 and HCC1806) are currently under evaluation.
- Prior Data: The Company referenced previous zebrafish xenograft studies showing statistically significant reductions in tumor growth and metastasis.
Outlook, Guidance, and Management Commentary
- IND Submission: The Company anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026.
- Next Steps: Activities include completing additional TNBC subtype evaluations, preparing a TNBC mouse xenograft study in a mammalian system, and continuing IND-enabling activities.
- Safety Profile: Completed GLP safety and toxicology studies in rats and dogs previously reported no treatment-related adverse toxicity.
Investor Verification Checklist
- Verify the timeline for the anticipated Q1 2026 IND submission.
- Confirm the results of the ongoing evaluations for BT-549 and HCC1806 cell lines.
- Monitor the design and initiation of the upcoming TNBC mouse xenograft study.
- Review the full data package regarding the iron-rescue mechanism to validate the proposed mode of action.